Anthracycline-induced Cardiomyopathy
📧 Sign up to get email alerts when something new happens for Anthracycline-induced Cardiomyopathy.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines [Phase 1]
Phase 1 clinical trial evaluating allogeneic bone marrow-derived mesenchymal stem cells to manage heart failure due to anthracycline-induced…
-
FDA approval · 2025-03-26FDA Approved: DEXRAZOXANE — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved a generic dexrazoxane (ANDA216748) from Novadoz Pharmaceuticals LLC under an original application.
-
CLINICAL_TRIALS withdrawal · 2024-05-20Clinical Trial Update: Prophylactic Lisinopril to Prevent Anthracycline Cardiomyopathy. [Phase 4]
Phase 4 trial evaluating prophylactic lisinopril for anthracycline-induced cardiomyopathy has been withdrawn.
-
CLINICAL_TRIALS research · 2018-05-31Clinical Trial Update: Detecting and Treating Subclinical Anthracycline Therapy Related Cardiac Dysfunction in Low Income Country. [Phase 3]
This clinical trial update describes a Phase 3 study sponsored by Makerere University investigating detection and treatment of subclinical a…
-
CLINICAL_TRIALS trial_result · 2014-02-10Clinical Trial Update: Resistance and Aerobic Exercise for Subclinical Anthracycline Cardiomyopathy [NA]
A completed clinical trial assessing whether resistance and aerobic exercise benefits individuals with subclinical anthracycline-induced car…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2014-02-04Clinical Trial Update: Spironolactone Against Anthracycline-induced Cardiomyopathy [Phase 4]
A Phase 4 trial evaluating spironolactone for anthracycline-induced cardiomyopathy has completed. The study was sponsored by TC Erciyes Univ…